The WHO standard: Universal access to rapid tuberculosis diagnostics sets benchmarks to achieve universal access to WHO-recommended rapid diagnostics (WRDs), increase bacteriologically confirmed tuberculosis and drug resistance detection, and reduce the time to diagnosis. WHO-recommended rapid diagn...ostics are highly accurate, cost-effective, reduce the time to treatment initiation, and impact patient-important outcomes.
more
UNAIDS 2019, Reference
This edition of UNAIDS data shows the results of some of those successes, but also the challenges that remain. It contains the very latest data on the world’s response to HIV, consolidating a small part of the huge volume of data collected, analysed and refined by UNAIDS ov...er the years. The full data set of information for 1990 to 2018 is available on aidsinfo.unaids.org.
more
Asylum and Migration Working Paper 1
October 2018
HIV testing services
Towards ending tuberculosis and multidrug-resistant tuberculosis.
national programmes for occupational health and safety for health workers: lessons learned from countries: summary report of the WHO online workshop, 15 July 2020
Alcohol misuses
Substance use disorders
Chapter G.1
New and updated information.
Adverse health effects of hot weather and heat-waves are largely preventable. Prevention requires a portfolio of actions at different levels:from health system preparedness, coordinated with meteorological early warning systems, to timely public ... and medical advice andimprovements to housing and urban planning. This publication offers detailed information for various target audiences, and on medicaladvice and treatment practices
more
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more